AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
23,071,000
22,090,000
22,465,000
23,002,000
24,708,000
Cost of Revenue
4,982,000
4,936,000
4,318,000
4,126,000
4,646,000
Gross Profit
18,089,000
17,154,000
18,147,000
18,876,000
20,062,000
Operating Expenses
Research Development
5,913,000
5,932,000
5,757,000
5,890,000
5,997,000
Selling General and Administrative
10,805,000
10,362,000
10,303,000
9,739,000
11,451,000
Total Operating Expenses
16,448,000
15,644,000
15,855,000
15,304,000
15,948,000
Operating Income or Loss
1,641,000
1,510,000
2,292,000
3,572,000
4,114,000
Interest Expense
806,000
796,000
713,000
680,000
1,075,000
Total Other Income/Expenses Net
-
-
-
-33,000
-16,000
Income Before Tax
2,106,000
1,993,000
2,227,000
3,552,000
3,069,000
Income Tax Expense
21,000
-57,000
-641,000
146,000
243,000
Income from Continuing Operations
2,085,000
2,050,000
2,868,000
3,406,000
2,826,000
Net Income
2,188,000
2,155,000
3,001,000
3,499,000
2,825,000
Net Income available to common shareholders
2,188,000
2,155,000
3,001,000
3,499,000
2,825,000
Reported EPS
Basic
-
0.85
1.19
1.39
1.11
Diluted
-
0.85
1.19
1.38
1.11
Weighted average shares outstanding
Basic
-
2,534,079
2,532,000
2,530,000
2,528,000
Diluted
-
2,534,079
2,534,000
2,532,000
2,530,000
EBITDA
-
6,542,000
5,976,000
6,589,000
6,996,000